27.95

1.62% -0.46

Kiniksa Pharmaceuticals International Plc (KNSA)

Overview News Price History Option Chain Financials Discussions Forecast

Kiniksa Pharmaceuticals International Plc stock is traded at $27.95, with a volume of 550.79K. It is down -1.62% in the last 24 hours and up +6.48% over the past month. Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

Previous Close:

$28.41

Open:

$28.15

24h Volume:

550.79K

Relative Volume:

0.87

Market Cap:

$2.17B

Revenue:

$384.10M

Net Income/Loss:

$-9.07M

P/E Ratio:

-199.64

EPS:

-0.14

Net Cash Flow:

$11.10M

1W Performance:

-6.11%

1M Performance:

+6.48%

6M Performance:

+36.41%

1Y Performance:

+50.84%

1-Day Range:

$27.65

$28.28

1-Week Range:

$26.54

$30.69

52-Week Range:

$17.38

$30.69

Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile

Name

Kiniksa Pharmaceuticals International Plc

Sector

Healthcare (1172)

Industry

Drug Manufacturers - Specialty & Generic (82)

Phone

(781) 431-9100

Address

23 OLD BOND STREET, FLOOR 3, LONDON

Employee

315

Twitter

@kiniksa

Next Earnings Date

2024-10-29

Latest SEC Filings

KNSA's Discussions on Twitter

Compare KNSA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KNSA Kiniksa Pharmaceuticals International Plc	27.95	2.17B	384.10M	-9.07M	11.10M	-0.14
RGC Regencell Bioscience Holdings Ltd	78.00	303.95B	0	-5.87M	-767.30K	-0.45
ZTS Zoetis Inc	161.67	74.39B	9.29B	2.52B	2.28B	5.57
HLN Haleon Plc Adr	10.50	48.97B	14.35B	1.85B	0	0.4023
TAK Takeda Pharmaceutical Co Adr	14.89	47.60B	30.08B	710.16M	4.45B	0.2182
TEVA Teva Pharmaceutical Industries Ltd Adr	16.89	20.17B	16.54B	-1.64B	749.00M	-1.45

Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-13-25	Initiated	Citigroup	Buy
Sep-13-24	Initiated	Jefferies	Buy
May-03-24	Initiated	Wells Fargo	Overweight
Jun-29-20	Reiterated	BofA Securities	Buy
Apr-01-20	Initiated	BofA/Merrill	Buy
Mar-11-19	Initiated	Barclays	Overweight
Dec-12-18	Reiterated	Wedbush	Outperform
Jun-19-18	Initiated	JMP Securities	Mkt Outperform

View All

Kiniksa Pharmaceuticals International Plc Stock (KNSA) Latest News

Jun 16, 2025

Kiniksa Pharmaceuticals: Arcalyst Performs, KPL-387 Advancing Fast (NASDAQ:KNSA) - Seeking Alpha

Jun 16, 2025

Jun 13, 2025

Lewis & Ellis acquires Huggins Actuarial Services - Yahoo

Jun 13, 2025

UK court rules insurers must pay more than $1bn for planes seized in Russia - Yahoo

Jun 13, 2025

Green Bay Packaging Executive Vice President Bryan Hollenbach to retire in August - Yahoo

Jun 12, 2025

Jio BlackRock gets nod to operate as investment adviser in India - Yahoo

Jun 12, 2025

Output of key food commodities “on course for new records” – FAO - Yahoo

Jun 12, 2025

Why Oklo Stock Dropped on Thursday - Yahoo

Jun 12, 2025

Medtech leaders unite on Capitol Hill to fight tariffs - Yahoo

Jun 12, 2025

Actabl launches new ProfitSword digital night audit feature for hotels - Yahoo

Jun 12, 2025

UCC Holding and Ashghal launch 3D Printed Schools Project in Qatar - Yahoo

Jun 12, 2025

Grant Thornton Advisors appoints new COO - Yahoo

Jun 12, 2025

Biggby Coffee unveils first brand refresh - Yahoo

Jun 12, 2025

Prime Drink Group’s bottling unit enters receivership - Yahoo

Jun 12, 2025

Del Taco expands to Louisville with new franchise agreement - Yahoo

Jun 12, 2025

Trump’s Treasury Sec Admits It’s Another TACO Day With China - Yahoo

Jun 12, 2025

Jun 11, 2025

Hakkers and Paebbl introduce carbon-storing solution at Port of Rotterdam - Yahoo

Jun 11, 2025

Mistral unveils Europe’s first AI reasoning model Magistral - Yahoo

Jun 11, 2025

Jun 10, 2025

Costco Announces Important Change for Certain Members Starting June 30 - Yahoo

Jun 10, 2025

Transcript : Kiniksa Pharmaceuticals International, plc Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 08 - marketscreener.com

Jun 10, 2025

MSD receives FDA approval for Enflonsia to prevent RSV - Yahoo

Jun 10, 2025

Jun 05, 2025

Kiniksa Pharmaceuticals Executives Sell Shares - TradingView

Jun 05, 2025

KNSA stock soars to 52-week high, hits $29.71 amid robust gains - Investing.com UK

Jun 05, 2025

Kiniksa sets Phase 2/3 trial for heart drug KPL-387 - Investing.com Nigeria

Jun 05, 2025

Kiniksa (KNSA) to Launch Phase 2/3 Trial for KPL-387 in 2025 | K - GuruFocus

Jun 05, 2025

Kiniksa Pharmaceuticals Announces Trial Design Of Planned Phase 2/3 Clinical Trial Of Kpl-387 In Recurrent Pericarditis - marketscreener.com

Jun 05, 2025

Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis | KNSA Stock News - GuruFocus

Jun 05, 2025

Kiniksa (KNSA) to Launch Phase 2/3 Trial for KPL-387 in 2025 | KNSA Stock News - GuruFocus

Jun 05, 2025

Kiniksa Pharmaceuticals Announces Trial Design of Planned - GlobeNewswire

Jun 05, 2025

Kiniksa Advances Revolutionary Monthly Dosing Treatment for Recurrent Pericarditis: Phase 2/3 Trial Details Released - Stock Titan

Jun 05, 2025

Jun 04, 2025

Louis Vuitton files lawsuit against Portuguese liqueur start-up over branding rights - Yahoo

Jun 04, 2025

Jun 03, 2025

Kiniksa Pharmaceuticals Annual Shareholders Meeting Decisions - TipRanks

Jun 03, 2025

May 29, 2025

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences - GlobeNewswire

May 29, 2025

Kiniksa Pharmaceuticals to Present at Jefferies and Goldman Sachs Healthcare Conferences in June - Stock Titan

May 29, 2025